ijms-logo

Journal Browser

Journal Browser

Molecular Mechanism Study of Natural Products for Human Health: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 921

Special Issue Editor


E-Mail
Guest Editor
Professor, Head of Department of Biochemistry, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Interests: nutrition and dietary components; herbal medicine; immunomodulatory potential of natural compounds; novel gene regulation; diabetes-related diseases; metabolic disease; inflammation; COPD; cancer therapy; cancer biology; regulation of p53; regulation of c-Myc
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Plant natural products have been used medically since the past, but most of the pharmaceutical market is mainly composed of synthetic drugs. Recently, interest in natural has been increasing, and various studies on their efficacy and molecular biological mechanisms have been conducted. Interestingly, natural drugs also serve as substitute for existing drugs and have the result of further enhancing the therapeutic effect. In addition, when it no longer works as a conventional treatment, natural products or herbal medicine can be effective as an alternative treatment. We invite all scientists working on molecular mechanism study of natural products to participate in this Special Issue. Original research articles or reviews on all aspects of the molecular and cellular mechanisms modulated by natural compounds are welcome. We look forward to your contributions.

Dr. Hyeung-Jin Jang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug discovery
  • natural compound
  • chemoprevention
  • herbal medicine
  • plant extract
  • novel gene

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

12 pages, 1414 KiB  
Review
Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight against Mycobacterium tuberculosis Infection?
by Lilitha Cebani and Nontobeko E. Mvubu
Int. J. Mol. Sci. 2024, 25(15), 8196; https://doi.org/10.3390/ijms25158196 - 27 Jul 2024
Viewed by 391
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), is a major global health issue, with around 10 million new cases annually. Advances in TB immunology have improved our understanding of host signaling pathways, leading to innovative therapeutic strategies. Inflammasomes, protein complexes [...] Read more.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), is a major global health issue, with around 10 million new cases annually. Advances in TB immunology have improved our understanding of host signaling pathways, leading to innovative therapeutic strategies. Inflammasomes, protein complexes organized by cytosolic pattern recognition receptors (PRRs), play a crucial role in the immune response to M. tb by activating caspase 1, which matures proinflammatory cytokines IL1β and IL18. While inflammation is necessary to fight infection, excessive or dysregulated inflammation can cause tissue damage, highlighting the need for precise inflammasome regulation. Drug-resistant TB strains have spurred research into adjunctive host-directed therapies (HDTs) that target inflammasome pathways to control inflammation. Canonical and non-canonical inflammasome pathways can trigger excessive inflammation, leading to immune system exhaustion and M. tb spread. Novel HDT interventions can leverage precision medicine by tailoring treatments to individual inflammasome responses. Studies show that medicinal plant derivatives like silybin, andrographolide, and micheliolide and small molecules such as OLT1177, INF39, CY-09, JJ002, Ac-YVAD-cmk, TAK-242, and MCC950 can modulate inflammasome activation. Molecular tools like gene silencing and knockouts may also be used for severe TB cases. This review explores these strategies as potential adjunctive HDTs in fighting TB. Full article
Show Figures

Figure 1

Back to TopTop